-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Treprostinil in Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Treprostinil in Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Treprostinil in Pulmonary Fibrosis Drug Details: Treprostinil (Tyvaso, Tyvaso DPI) is...
-
Product Insights
NewDry Powder Inhaler Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder. GlobalData's Medical Devices sector report, “Dry Powder Inhaler Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" provides comprehensive information about the Dry Powder Inhaler Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Dry Powder Inhaler Devices report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Glycopyrrolate in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Glycopyrrolate in Asthma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Glycopyrrolate in Asthma Drug Details: Glycopyrronium bromide (Seebri / NVA237 / AD237...
-
Product Insights
NewVerona Pharma Plc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Verona Pharma Plc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Verona Pharma Plc (Verona Pharma) is a clinical-stage biopharmaceutical company that focuses on the development and marketing of therapies for the treatment of respiratory diseases. The company’s lead investigating candidate, ensifentrine, a bronchodilator/anti-inflammatory agent intended for the treatment of chronic obstructive pulmonary disease (COPD) in Phase III clinical trials; additional formulations of ensifentrine for the treatment of COPD: a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vardenafil Hydrochloride in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vardenafil Hydrochloride in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vardenafil Hydrochloride in Pulmonary Arterial Hypertension Drug Details: Vardenafil hydrochloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Treprostinil in Pulmonary Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Treprostinil in Pulmonary Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Treprostinil in Pulmonary Hypertension Drug Details: Treprostinil (Yutrepia) is a prostacyclin analog...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Baqsimi in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Baqsimi in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Baqsimi in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...
-
Product Insights
DPI Hai Phong – Thuy Nguyen Performance and Conference Center – Hai Phong
Equip yourself with the essential tools needed to make informed and profitable decisions with our DPI Hai Phong – Thuy Nguyen Performance and Conference Center – Hai Phong report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CHF-6333 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CHF-6333 in Cystic Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CHF-6333 in Cystic Fibrosis Drug Details: CHF-6333 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CHF-6333 in Bronchiectasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CHF-6333 in Bronchiectasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CHF-6333 in Bronchiectasis Drug Details: CHF-6333 is under development for the treatment of...